Literature DB >> 12052067

Free sulfhydryl in recombinant monoclonal antibodies.

Wei Zhang1, Marta J Czupryn.   

Abstract

Monoclonal antibody (mAb) therapy applications have been growing rapidly in recent years. Like other recombinant protein drugs, therapeutic mAb's need to be well characterized to ensure their structural and functional integrity. IgG mAb's are composed of two heavy and two light chains covalently linked by interchain disulfide bonds. Each domain of the heavy or light chain contains one additional disulfide bond. Native IgG mAb's, with completely formed disulfide bonds, should not bear any free sulfhydryl. This report describes detection and quantification of free sulfhydryl in recombinant mAb's produced in Chinese hamster ovary (CHO) cells using a fluorescent technique. The method utilizes the fluorescent probe N-(1-pyrenyl)maleimide (NPM). The purified mAb's appear to be homogeneous under native conditions with approximately 0.02 mol of free sulfhydryl per mole of protein. Upon denaturation, minor species related to the mAb's are observed on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the free sulfhydryl level is determined to be approximately 0.1 mol/mol of protein. These results suggest that a small portion of these recombinant mAb's lack in intermolecular disulfide bonds but remain noncovalently associated under native conditions. The formation of the free sulfhydryl containing mAb species is likely to occur during the culture process and/or protein folding process in the endoplasmic reticulum (ER).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052067     DOI: 10.1021/bp025511z

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  21 in total

1.  Functional recombinant human anti-HBV antibody expressed in milk of transgenic mice.

Authors:  Ran Zhang; Dan Cui; Hong Wang; Chuan Li; Xin Yao; Yaofeng Zhao; Mifang Liang; Ning Li
Journal:  Transgenic Res       Date:  2012-10       Impact factor: 2.788

2.  Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry.

Authors:  Lintao Wang; Godfrey Amphlett; John M Lambert; Walter Blättler; Wei Zhang
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

Review 3.  Protein aggregation and bioprocessing.

Authors:  Mary E M Cromwell; Eric Hilario; Fred Jacobson
Journal:  AAPS J       Date:  2006-09-15       Impact factor: 4.009

4.  Unbiased in-depth characterization of CEX fractions from a stressed monoclonal antibody by mass spectrometry.

Authors:  François Griaud; Blandine Denefeld; Manuel Lang; Héloïse Hensinger; Peter Haberl; Matthias Berg
Journal:  MAbs       Date:  2017-04-05       Impact factor: 5.857

5.  Cysteinylation of a monoclonal antibody leads to its inactivation.

Authors:  Troy McSherry; Jennifer McSherry; Panfilo Ozaeta; Kenton Longenecker; Carol Ramsay; Jeffrey Fishpaugh; Steven Allen
Journal:  MAbs       Date:  2016-04-06       Impact factor: 5.857

6.  Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.

Authors:  Leslie A Khawli; Sirj Goswami; Ryan Hutchinson; Zephania W Kwong; Jihong Yang; Xiangdan Wang; Zhenling Yao; Alavattam Sreedhara; Tony Cano; Devin Tesar; Ihsan Nijem; David E Allison; Pin Yee Wong; Yung-Hsiang Kao; Cynthia Quan; Amita Joshi; Reed J Harris; Paul Motchnik
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

7.  Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates.

Authors:  Heather Franey; Stephen R Brych; Carl G Kolvenbach; Rahul S Rajan
Journal:  Protein Sci       Date:  2010-09       Impact factor: 6.725

8.  Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain.

Authors:  Arnold McAuley; Jaby Jacob; Carl G Kolvenbach; Kimberly Westland; Hyo Jin Lee; Stephen R Brych; Douglas Rehder; Gerd R Kleemann; David N Brems; Masazumi Matsumura
Journal:  Protein Sci       Date:  2008-01       Impact factor: 6.725

9.  Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches.

Authors:  Chen Li; Anthony Rossomando; Shiaw-Lin Wu; Barry L Karger
Journal:  MAbs       Date:  2013-04-25       Impact factor: 5.857

10.  Rendering protein-based particles transiently insoluble for therapeutic applications.

Authors:  Jing Xu; Jin Wang; J Christopher Luft; Shaomin Tian; Gary Owens; Ashish A Pandya; Peter Berglund; Patrick Pohlhaus; Benjamin W Maynor; Jonathan Smith; Bolyn Hubby; Mary E Napier; Joseph M DeSimone
Journal:  J Am Chem Soc       Date:  2012-05-17       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.